Tokyo, Japan AnGes Inc appeared to be the Corporate Investor, which was created in 1999. The company was established in Asia in Japan. The main office of represented Corporate Investor is situated in the Tokyo.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - Germany. Among the various public portfolio startups of the fund, we may underline Dolthera GmbH Among the most successful fund investment fields, there are Health Care, Pharmaceutical. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2005.
The standard case for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Innovations Kapital, Deutsche Venture Capital. In the next rounds fund is usually obtained by German Federal Ministry of Education and Research (BMBF).
Related Funds
| Fund Name | Location |
| Asset Management Associates | California, Palo Alto, United States |
| Blue Focus PR Consulting | Beijing, Beijing, China |
| Clean Energy Venture Group | Brookline, Massachusetts, United States |
| CreativeCubes.Co | Australia, Richmond, Victoria |
| Derayah Capital | Ar Riyad, Riyadh, Saudi Arabia |
| FLAG Capital Management | Connecticut, Stamford, United States |
| Grameen Foundation | District of Columbia, United States, Washington |
| Growth Finance Fund | - |
| Hattery | California, San Francisco, United States |
| Lewis & Clark AgriFood | Missouri, St Louis, United States |
| Montgomery County Department of Economic Development | Maryland, Rockville, United States |
| MX Capital | - |
| Poly Capital | China, Guangdong, Guangzhou |
| Shikong Wuxing | China, Shanghai |
| Tian Yin Music | - |
| TNB Ventures | Central, Central Region, Singapore |
| Wealth Well | Ar Riyad, Riyadh, Saudi Arabia |
| Xinkeyuan | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Emendo Biotherapeutics | $61M | 15 Jan 2020 | New York, United States | ||
MyBiotics Pharma | $8M | 15 Aug 2018 | Rehovot, HaMerkaz, Israel | ||
Dolthera GmbH | $17M | 12 Aug 2005 | Bavaria |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Emendo Biotherapeutics | $61M | 15 Jan 2020 | New York, United States | ||
MyBiotics Pharma | $8M | 15 Aug 2018 | Rehovot, HaMerkaz, Israel | ||
Dolthera GmbH | $17M | 12 Aug 2005 | Bavaria |
